ReviewCurrent drug targets2026
Biomarkers as Drivers of Innovation in Modern Diagnostics and Therapeutics.
Review in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBiomarkers have revolutionized diagnostics and therapeutics by enabling early detection, prognosis, and treatment monitoring across a range of diseases, including cancer and neurodegenerative disorders. Their role in personalized medicine underscores their importance in modern healthcare.
methodsThis review consolidates findings from diverse sources, exploring the classes, mechanisms, and emerging technologies for biomarker discovery. Techniques such as next-generation sequencing, immunohistochemistry, and mass spectrometry were critically evaluated for their efficiency in biomarker validation.
resultsThe study identifies various cancer biomarkers, including genetic, proteomic, and metabolomic markers, and highlights their clinical applications. It underscores significant breakthroughs in non-invasive diagnostic tools, such as exosomal proteins, miRNAs, and saliva-based markers. Challenges such as limited sample sizes, regulatory hurdles, and clinical translation bottlenecks were also discussed. DISCUSSION: Despite significant advancements, integrating biomarkers into clinical practice remains challenging due to issues of specificity, sensitivity, and cost-effectiveness. Emerging approaches such as immune checkpoint inhibitors, tumor mutational burden assessments, and chemokine profiling have shown potential in enhancing cancer immunotherapy outcomes.
conclusionBiomarkers are pivotal in advancing personalized medicine by refining diagnostic and therapeutic strategies. Addressing current limitations through innovative technologies and interdisciplinary collaboration can unlock their full potential, transforming disease management and patient care.
Indexed as
Identifiers
41486997What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.